A carregar...
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration resistant prostate cancer
After initial response to androgen receptor targeting drugs abiraterone or enzalutamide, most patients develop progressive disease and therefore, castration resistant prostate cancer (CRPC) remains a terminal disease. Multiple mechanisms underlying acquired resistance have been postulated. Intratumo...
Na minha lista:
| Publicado no: | Expert Rev Anticancer Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4221359/ https://ncbi.nlm.nih.gov/pubmed/24927631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2014.928594 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|